| Autor: |
Michael Praktiknjo, Ana S. Pena Solano, Farsaneh Sadeghlar, Thomas Welchowski, Matthias Schmid, Christian Möhring, Taotao Zhou, Robert Mahn, Malte B. Monin, Carsten Meyer, Georg Feldmann, Peter Brossart, Cornelius Beekum, Alexander Semaan, Hanno Matthaei, Steffen Manekeller, Alois M. Sprinkart, Sebastian Nowak, Julian Luetkens, Jörg C. Kalff, Christian P. Strassburg, Maria A. Gonzalez -Carmona |
| Rok vydání: |
2023 |
| Popis: |
Lenvatinib is a multiple receptor tyrosine kinase inhibitor (TKI) approved for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). TKI are suspected of exacerbating muscle wasting (sarcopenia) in patients with cancer. In this study, we analyze the role of sarcopenia in patients with advanced HCC treated with lenvatinib. This is a retrospective analysis of a real-life cohort of 25 patients with advanced HCC who were treated with lenvatinib from 2018 to November 2020 in Germany. Patients were stratified for loss of skeletal muscle index (SMI) during the first three months of lenvatinib therapy. Overall survival (OS), progression-free survival (PFS) and toxicity were analyzed for all patients, especially regarding development of sarcopenia before and during the first three months of therapy with lenvatinib. Three months after beginning of therapy with lenvatinib, a significant reduction of muscle mass was observed in 60% of patients (p = 0.035). Despite increase of sarcopenia, patients benefitted from lenvatinib in our cohort of patients in terms of OS and PFS and did not experience increased toxicity. Furthermore, muscle loss was not found to be a negative predictor of survival in the univariate analysis. Patients with advanced hepatocellular carcinoma experience muscle wasting with lenvatinib therapy. However, despite progressive sarcopenia, patients benefit from a therapy with lenvatinib in terms of OS and PFS without increased toxicity. However, assessment and prophylaxis of skeletal muscle status should be recommended during a therapy with lenvatinib. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
